| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
| Targets |
PRMT5 (protein arginine methyltransferase 5); the inhibitor binds to the PRMT5/MEP50 complex and blocks methyltransferase activity, with IC50 values in the low nanomolar range reported for related chemotypes.
|
|---|---|
| ln Vitro |
PRMT5-IN-1 HCl inhibits PRMT5-mediated methylation of histone H4R3 or other substrates in cell-free enzymatic assays. In cancer cell lines, it reduces symmetric dimethylarginine (SDMA) levels and inhibits proliferation, with enhanced sensitivity in MTAP-deleted cells.
|
| ln Vivo |
In vivo, PRMT5 inhibitors related to this chemotype have shown antitumor activity in xenograft models, including MTAP-deleted tumors. PRMT5-IN-1 HCl is expected to reduce tumor SDMA levels and suppress growth at tolerated doses.
|
| Enzyme Assay |
Recombinant PRMT5/MEP50 complex is incubated with S-adenosylmethionine and a peptide substrate in the presence of serial dilutions of PRMT5-IN-1 HCl. Methylated product is detected by fluorescence or radioactivity, and IC50 values are derived.
|
| Cell Assay |
Cancer cells are treated with PRMT5-IN-1 HCl for 48–72 hours, and SDMA levels are measured by immunofluorescence or Western blotting. Cell viability is assessed by ATP-based assays, and apoptosis markers are analyzed.
|
| Animal Protocol |
Mice bearing MTAP-deleted tumor xenografts receive PRMT5-IN-1 HCl by intraperitoneal or oral administration. Tumor volume is monitored, and tumor tissue is analyzed for SDMA reduction to confirm target engagement.
|
| References |
| Molecular Formula |
C19H20CL2N4O5
|
|---|---|
| Molecular Weight |
455.29
|
| Related CAS # |
PRMT5-IN-1; 2366149-83-7
|
| Appearance |
Off-white to pink solid powder
|
| SMILES |
O[C@@H]1[C@@H](O)[C@H](N2C=CC3=C2N=CN4C3=NCC4O)O[C@H]1C[C@H](C5=CC=C(Cl)C=C5)O.Cl
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: ~125 mg/mL (~266.3 mM; with ultrasonication)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80: Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 :Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400  (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.1964 mL | 10.9820 mL | 21.9640 mL | |
| 5 mM | 0.4393 mL | 2.1964 mL | 4.3928 mL | |
| 10 mM | 0.2196 mL | 1.0982 mL | 2.1964 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.